Oral premalignancy: New methods of detection and treatment

Current Oncology Reports

Volumn 8, Issue 2, 2006, Pages 146-154

  Gillenwater, Ann ^a   Papadimitrakopoulou, Vali ^b   Richards Kortum, Rebecca ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BOWMAN BIRK INHIBITOR; CURCUMIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIGALLOCATECHIN GALLATE; HEMATOPORPHYRIN DERIVATIVE; ISOTRETINOIN; ONYX 015; PHOTOSENSITIZING AGENT; PLACEBO; TOLONIUM CHLORIDE;

CANCER DIAGNOSIS; CANCER INVASION; CANCER THERAPY; CARCINOGENESIS; CHEMOLUMINESCENCE; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CLINICAL TRIAL; CONFOCAL MICROSCOPY; CYTOLOGY; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TARGETING; EARLY DIAGNOSIS; FLUORESCENCE ANALYSIS; GENE TARGETING; HUMAN; MOUTH CANCER; MOUTH CAVITY; OPTICAL COHERENCE TOMOGRAPHY; ORAL BIOPSY; ORAL SURGERY; OUTCOMES RESEARCH; PHOTODYNAMIC THERAPY; PHOTODYNAMICS; PRECANCER; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STAINING; UNSPECIFIED SIDE EFFECT;

CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MASS SCREENING; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS;

EID: 33645542283     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-006-0050-4     Document Type: Review

References (85)

1. Vogelstein B, Kinzler KW: The multistep nature of cancer trends. Genet (England) 1993, 9:38-41.
2. Califano J, van der Riet P, Westra W, et al.: Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res 1996, 56:2488-2492.
3. Braakhuis BJM, Leemans CR, Brakenhoff RH: A genetic progression model of oral cancer: current evidence and clinical implications. J Oral Pathol Med 2004, 33:317-322.
4. Lippman SM, Hong WK: Molecular markers of the risk of oral cancer. N Engl J Med 2001, 344:1323-1326.
5. Lippman SM, Sudbo J, Hong WK: Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol 2005, 23:346-356.
6. Banerjee AG, Bhattacharyya I, Vishwanatha JK: Identification of genes and molecular pathways involved in the progression of premalignant oral epithelia. Mol Cancer Ther 2005, 4:865-875.
7. Slaughter OP: Multicentric origin of intraoral carcinoma. Surgery 1946, 20:133-146.
8. Strong MS, Incze J, Vaughan CN: Field cancerization in the aerodigestive tract - its etiology, manifestation, and significance. J Otolaryngol 1984, 13:1-6.
9. Incze J, Vaughan CW Jr, Lui P, et al.: Premalignant changes in normal appearing epithelium in patients with squamous cell carcinoma of the upper aerodigestive tract. Am J Surg 1982, 144:401-405.
10. Westra WH, Sidransky D: Phenotypic and genotypic disparity in premalignant lesions: Of calm water and crocodiles. J Natl Cancer Inst 1998, 90:1500-1501.
11. Reibel J: Prognosis of oral pre-malignant lesions: Significance for clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med 2003, 14(1):47-62.
12. Silverman S, Gorsky M, Lozada F: Oral leukoplakia and malignant transformation: A follow-up study of 257 patients. Cancer 1984, 53:563-568.
13. Reichart PA, Philipsen HP: Oral erythroplakia: A review. Oral Oncol 2005, 41:551-561.
14. Axell T, Pindborg JJ, Smith CJ, van der Waal I: Oral white lesions with special reference to precancerous and tobacco-related lesions: Conclusions of an international symposium held in Uppsala, Sweden, May 18-21 1994. International Collaborative Group on Oral White Lesions. J Oral Pathol Med 1996, 25:49-54.
15. Van der Waal I, Schepman KP, van der Meij EH: A modified classification and staging system for oral leukoplakia. Oral Oncol 2000, 36:264-266.
16. Scully C, Sudbo J, Speight PM: Progress in determining the malignant potential of oral lesions. J Oral Pathol Med 2003, 32:251-256.
17. Sudbo J, Kildal W, Risberg B, et al.: DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med 2001, 344:1270-1278.
18. Lee JJ, Hong WK, Hittelman WN, et al.: Predicting cancer development in oral leukoplakia: Ten years of translational research. Clin Cancer Res 2000, 6:1702-1710.
19. Lam S, MacAulay C, leRiche JC, Palcic B: Detection and localization of early lung cancer by fluorescence bronchoscopy. Cancer 2000, 89 (11 Suppl):2468-2473.
20. Stanzel F: Fluorescent bronchoscopy: Contribution for lung cancer screening? Lung Cancer 2004, 45 (Suppl 2): S29-S37.
21. Bogaards A, Varma A, Zhang K, et al.: Fluorescence image-guided brain tumor resection with adjuvant metronomic photodynamic therapy: Pre-clinical model and technology development. Photochem Photobiol Sci 2005, 4:438-442.
22. Kara MA, Smits ME, Rosmolen WD, et al.: A randomized crossover study comparing light-induced fluorescence endoscopy with standard videoendoscopy for the detection of early neoplasia in Barrett's esophagus. Gastrointest Endosc 2005, 61:671-678.
23. Kulapaditharom B, Boonkitticharoen V: Laser-induced fluorescence imaging in localization of head and neck cancers. Ann Otol Rhinol Laryngol 1998, 107:241-246.
24. Onizawa K, Saginoya H, Furuya Y, et al.: Usefulness of fluorescence photography for diagnosis of oral cancer. Int J Oral Maxillofac Surg 1999, 28:206-210.
25. Svistun E, Alizadeh-Naderi R, El-Naggar A, et al.: Vision enhancement system for detection or oral cavity neoplasia based on autofluorescence. Head Neck 2004, 26:205-215.
26. Wagnieres GA, Star WM, Wilson BC: In vivo fluorescence spectroscopy and imaging for oncological applications. Photochem Photobiol 1998, 68:603-632.
27. Ramanujam N: Fluorescence spectroscopy of neoplastic and non-neoplastic tissues. Neoplasia 2000, 2:89-117.
28. Schantz SP, Kolli V, Savage HE, et al.: In vivo native cellular fluorescence and histological characteristics of head and neck cancer. Clin Cancer Res 1998, 4:1177-1182.
29. Dhingra JK, Perrault DF Jr, McMillan K, et al.: Early diagnosis of upper aerodigestive tract cancer by autofluorescence. Arch Otolaryngol Head Neck Surg 1996, 122:1181-1186.
30. Gillenwater AM, Jacob R, Ganeshappa R, et al.: Noninvasive diagnosis of oral neoplasia based on fluorescence spectroscopy and native tissue autofluorescence. Arch Otolaryngol Head Neck Surg 1998, 124:1251-1258.
31. Heintzelman D, Utzinger U, Fuchs H, et al.: Optimal excitation wavelengths for in vivo detection of oral neoplasia using fluorescence spectroscopy. Photochem Photobiol 2000, 72:103-113.
32. Sokolov K, Drezek R, Gossage K, Richards-Kortum R: Reflectance spectroscopy with polarized light: Is it sensitive to cellular and nuclear morphology? Opt Expr 1999, 5:302-317.
33. Gurjar RS, Backman V, Perelman LT, et al.: Imaging human epithelial properties with polarized light-scattering spectroscopy. Nat Med 2001, 7:1245-1248.
34. Muller MG, Valdez TA, Georgakoudi I, et al.: Spectroscopic detection and evaluation of morphologic and biochemical changes in early human oral carcinoma. Cancer 2003, 97:1681-1692.
35. Georgakoudi I, Jacobson BC, Van Dan J, et al.: Fluorescence, reflectance, and light-scattering spectroscopy for evaluating dysplasia in patients with Barrett's esophagus. Gastroenterology 2001, 120:1620-1629.
36. Chang SK, Mirabal YN, Atkinson EN, et al.: Combined reflectance and fluorescence spectroscopy for in vivo detection of cervical pre-cancer. J Biomed Opt 2005, 10:024-031.
37. Rosenberg D, Cretin S: Use of meta-analysis to evaluate tolonium chloride in oral cancer screening. Oral Surg Oral Med Oral Pathol 1987, 67:621-627.
38. Epstein JB, Scully C, Spinelli JJ: Toluidine blue and Lugol's iodine application in the assessment of oral malignant disease and lesions at risk of malignancy. J Oral Pathol Med 1992, 21:160-163.
39. Zhang L, Williams M, Poh CF, et al.: Toluidine blue staining identifies high-risk primary oral premalignant lesions with poor outcome. Cancer Res 2005, 65:8017-8021.
40. Leunig A, Betz CS, Mehlmann M, et al.: Detection of squamous cell carcinoma of the oral cavity by imaging 5-aminolevulinic add-induced protoporphyrin IX fluorescence. Laryngoscope 2000, 1100:78-83.
41. Zheng W, Olivo M, Soo KC: The use of digitized endoscopic imaging of 5-ALA-induced PPIX fluorescence to detect and diagnose oral premalignant and malignant lesions in vivo. Int J Cancer 2004, 110:295-300.
42. Huber MA, Bsoul SA, Terezhalmy GT: Acetic acid wash and chemiluminescent illumination as an adjunct to conventional oral soft tissue examination for the detection of dysplasia: Pilot study. Quintessence Int 2004, 35:378-384.
43. Sokolov K, Aaron J, Hsu B, et al.: Optical systems for in vivo molecular imaging of cancer. Technol Cancer Res Treat 2003, 2:491-504.
44. Soukos NS, Hamblin MR, Keel S, et al.: Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo. Cancer Res 2001, 61:4490-4496.
45. Hsu ER, Anslyn EV, Dharmawardhane S, et al.: A far-red fluorescent contrast agent to image epidermal growth factor receptor expression. Photochem Photobiol 2004, 79:272-279.
46. Sokolov K, Follen M, Aaron J, et al.: Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. Cancer Res 2003, 63:1999-2004.
47. El-Sayed IH, Huang X, El-Sayed AM: Surface plasmon resonance scattering and absorption of anti-EGF antibody conjugated gold nanoparticles in cancer diagnostics: Applications in oral cancer. Nano Lett 2005, 5:829-834.
48. Sciubba JJ: Improving detection of precancerous and cancerous oral lesions. Computer-assisted analysis of the oral brush biopsy. U.S. Collaborative OralCDx Study Group. J Am Dent Assoc 1999, 130:1445-2457.
49. Poate TWJ, Buchanan JAG, Hodgson TA, et al.: An audit of the efficacy of the oral brush biopsy technique in a specialist Oral Medicine unit. Oral Oncol 2004, 40:829-834.
50. Potter TJ, Summerlin D-J, Campbell JH: Oral malignancies associated with negative transepithelial brush biopsy. J Oral Maxillofac Surg 2003, 61:674-677.
51. Clark AL, Gillenwater AM, CollierTC, et al.: Confocal microscopy for real-time detection of oral cavity neoplasia. Clin Cancer Res 2003, 9:4714-4721.
52. Colston BW Jr, Everett MJ, Sathyam US, et al.: Imaging of the oral cavity using optical coherence tomography. Mogr Oral Sci 2000, 17:32-55.
53. Wilder-Smith, Jung WG, Brenner M, et al.: In vivo optical coherence tomography for the diagnosis of oral malignancy. Laser Surg Med 2004, 35:269-275.
54. Li Y, St. John MAR, Zhou X, et al.: Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res 2004, 10:8442-8450.
55. El-Naggar AK, Mao L, Staerkel G, et al.: Genetic heterogeneity in saliva from patients with oral squamous carcinomas: Implications in molecular diagnosis and screening. J Mol Diagn 2001, 3:164-170.
56. Spafford MF, Koch WM, Reed AL, et al.: Detection of head and neck squamous cell carcinoma among exfoliated oral mucosal cells by microsatellite analysis. Clin Cancer Res 2001, 7:607-612.
57. Tradati N, Grigolat R, Calabrese L, et al.: Oral leukoplakias: To treat or not? Oral Oncol 1997, 33:317-321.
58. Van der Hem PS, Nauta JM, van der Wal JE, Roodenburg JLN: The results of CO2 laser surgery in patients with oral leukoplakia: A 25 year follow up. Oral Oncol 2005, 41:31-37.
59. Vedtofte P, Holmstrup P, Hjorting-Hansen E, Pindborg JJ: Surgical treatment of premalignant lesions of the oral mucosa. Int J Oral Maxillofac Surg 1987, 16:656-664.
60. Sudbo J, Lippman SM, Lee JL et al.: The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med 2004, 350:1405-1413.
61. Zhang L, Poh CF, Lam WL, et al.: Impact of localized treatment in reducing risk of progression of low-grade oral dysplasia: Molecular evidence of incomplete resection. Oral Oncol 2001, 37:505-512.
62. Dolmans DEJGJ, Fukumura D, Jain RK: Photodynamic therapy for cancer. Nat Rev Cancer 2003, 3:380-386.
63. Kubler A, Haase T, Rheinwald M, et al.: Treatment of oral leukoplakia by topical application of 5-aminolevulinic acid. Int J Oral Maxillofac Surg 1998, 27:466-469.
64. Fan KF, Hopper C, Speight PM, et al.: Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity. Cancer 1996, 78:1374-1383.
65. Sieron A, Adamek M, Kawczyk-Krupka A, et al.: Photodynamic therapy (PDT) using topically applied g-aminolevulinic acid (ALA) for the treatment of oral leukoplakia. J Oral Pathol Med 2003, 32:330-336.
66. Hong WK, Endicott J, Itri LM, et al.: 13-cis retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986, 315:1501-1505.
67. Lippman SM, Bastsakis JG, Toth BB, et al.: Comparison of low-dose isoretinoin therapy with beta carotene to prevent oral carcinogenesis. N Engl J Med 1993, 328:15-20.
68. Papadimitrikopoulou VA, Hong WK, Lee JS, et al.: Low dose isoretinoin versus beta carotene to prevent oral carcinogenesis: Long term follow up. J Natl Cancer Inst 1997, 89:257-258.
69. Chiesa F, Tradati N, Marazza M, et al.: Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J Cell Biochem Suppl 1993, 17F:255-261.
70. Mao L, El-Naggar AK, Papadmitrakopoulou V, et al.: Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 1998, 90:1545-1551.
71. Benner SE, Winn RJ, Lippman SM, et al.: Regression of oral leukoplakia with alpha-tocopherol: A community clinical oncology program chemoprevention study. J Natl Cancer Inst 1993, 85:44-47.
72. Armstrong WB, Kennedy AR, Wan XS, et al.: Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 2000, 6:4684-4691.
73. Cheng AL, Hsu CH, Lin JK, et al.: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21:2895-2900.
74. Rudin CM, Cohen EEX, Papdimitrakopoulou VA, et al.: An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 2003, 21:4546-4552.
75. Papadimitrakopoulou VA: Chemoprevention of head and neck cancer: An update. Curr Opin Oncol 2002, 14:318-322.
76. Rhee JC, Khuri FR, Shin DM: Advances in chemoprevention of head and neck cancer. Oncologist 2004, 9:302-311.
77. Wang Z: The role of COX-2 in oral cancer development, and chemoprevention/treatment of oral cancer by selective COX-2 inhibitors. Curr Pharm Des 2005, 11:1771-1777.
78. Lippman SM, Gibson N, Subbaramaiah K, Dannenberg AJ: Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways. Clin Cancer Res 2005, 11:6097-6099.
79. Chan G, Boyle JO, Yang EK, et al.: Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999, 59:991-994.
80. Nishimura N, Manno Y, Takaoka K, et al.: Increased expression of cyclooxygenase (COX)-2 in DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib. J Oral Pathol Med 2004, 33:614-621.
81. Mulshine JL, Atkinson JC, Greer RO, et al.: Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res 2004, 10:1565-1573.
82. Shin DM, Ro JY, Hong WK, Hittleman WN: Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994, 54:3153-3159.
83. Dassonville O, Formento JL, Francoual M, et al.: Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993, 11:1873-1878.
84. Pomerantz RG, Grandis JR: The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy. Semin Oncol 2004, 31:734-743.
85. Choe MS, Zhang X, Shin HJ, et al.: Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 2005, 4:1448-1455.